Stock ideas

Iqvia Holdings Inc.

IQV is a leading life-science services provider showing steady mid-single-digit revenue growth with recent YoY pickup and a confirmed Stage-2 uptrend backed by strong relative strength.

Genmab A/S

Genmab is emerging as a Biotech Therapeutics leader as sustained institutional accumulation and strong relative strength have pushed shares near a 52-week high in a confirmed uptrend.

Microsoft Corp

Microsoft's sustained mid-teens revenue growth, high institutional ownership, and leading cloud footprint position it as a timely leader in Cloud & Hosting Infrastructure themes.

Insperity, Inc.

Insperity is a leading HR outsourcing and services provider whose steady service revenue, strong institutional accumulation, and confirmed technical uptrend make it a timely enterprise HR-services leader.

Trinet Group, Inc.

Trinet combines enterprise-focused HR services with re-accelerating GAAP quarterly EPS growth, heavy institutional ownership, and an established Stage 2 uptrend within Enterprise & Vertical Software.

Manhattan Associates Inc

Manhattan Associates pairs accelerating revenue growth with an established Stage 2 technical uptrend, making it a timely leader in enterprise logistics and vertical software solutions.

Medpace Holdings, Inc.

Medpace, a clinical research services leader, combines consistent double-digit revenue growth and high institutional ownership, making it a timely leader in Life Science Tools & CDMO.

Argenx Se

Argenx's validated Stage 1→2 breakout, reclaimed 200-day trend, and substantial institutional ownership position it as a timely technical leader within Biotech Therapeutics with improving relative strength.

Bio-Rad Laboratories, Inc.

Bio‑Rad is a leading life‑science tools company with steady quarterly revenue, heavy institutional ownership, and recent strong relative performance versus the S&P, positioning it as a timely theme leader.

Bruker Corp

Bruker is positioned as a life-science tools leader with accelerating revenue, a confirmed uptrend, and heavy institutional sponsorship that has driven strong relative performance versus the S&P.

F5, Inc.

F5 is a cybersecurity-focused application delivery and security vendor with recent year-over-year revenue gains, an established technical uptrend, and above-market relative strength versus the S&P 500.

Thermo Fisher Scientific Inc.

Thermo Fisher is a leading life-science tools and CDMO provider whose revenue acceleration to double-digit year-over-year growth and heavy institutional ownership make it a timely sector leader.

BOX Inc

BOX Inc is a cloud content-management leader with steady mid-to-high single-digit revenue growth and improving GAAP EPS, positioning it as a timely enterprise software leader in cloud content services.

Twilio Inc

Twilio shows accelerating revenue and GAAP EPS growth, now delivering more than 20% quarterly revenue gains with strong institutional ownership, positioning it as a leader in enterprise communications software.

Roivant Sciences Ltd.

Roivant is a technically leading, institutionally held biotech whose stock has outperformed the market while near-term revenue and GAAP EPS remain weak and volatile.

Agilent Technologies, Inc.

Agilent is a leading laboratory-instrument supplier positioned to benefit from recovering life-science demand after a multi-quarter revenue inflection and very high institutional ownership.

Zebra Technologies Corp

Zebra Technologies is a leader in data-capture hardware and automation software, with accelerating revenue and GAAP diluted EPS that validate its role in industrial automation growth trends.

Kiniksa Pharmaceuticals International, plc

Kiniksa is a mid-cap therapeutics company showing sustained double-digit quarterly revenue growth, improving GAAP profitability, and strong relative strength versus the S&P 500 as a theme leader.

Sotera Health Co

Sotera Health's steady revenue increases, accelerating GAAP diluted EPS and strong institutional sponsorship, combined with an established uptrend, position it as a timely leader in Life Science Tools & CDMO services.

Protagonist Therapeutics, Inc

Protagonist Therapeutics is a biotech therapeutics leader trading in an established uptrend with strong relative strength, intermittent GAAP profitability, and a recovering revenue run-rate that merits watching.

Dropbox, Inc.

Dropbox is positioned for renewed enterprise software momentum after sequential revenue acceleration and a validated Stage 1 to 2 base breakout backed by strong demand volume.

Tg Therapeutics, Inc.

Tg Therapeutics has shifted to commercial growth, with quarterly revenue rising from $63.5M in 2024Q1 to $240.3M in 2026Q2 and substantial institutional sponsorship.

Arrowhead Pharmaceuticals, Inc.

Arrowhead has moved into material reported revenue and improving GAAP diluted EPS while trading in an established uptrend with heavy institutional ownership and strong relative strength.

Exelixis, Inc.

Exelixis pairs steady mid-teens revenue growth and rising GAAP diluted EPS with a confirmed Stage‑2 technical uptrend and strong relative strength within oncology therapeutics.

Krystal Biotech, Inc.

Krystal Biotech is a commercial-stage gene therapy company that grew quarterly revenue from $8.6M to $119.2M while delivering consecutive GAAP profits, positioning it as a timely leader in dermatology biotech.

Baxter International Inc

Baxter pairs steady mid-single-digit revenue growth with a validated Stage 1→2 breakout, supported by 2.7x base demand and a reclaimed 200-day average, making it a timely leader in medical devices.

Acadia Pharmaceuticals Inc

Acadia shows steady mid-single- to mid-teens revenue growth, heavy institutional sponsorship, and a validated Stage 1→2 breakout, positioning it as a timely leader in Biotech Therapeutics.

Paychex Inc

Paychex is a payroll and HR-software leader showing accelerating revenue and recovering GAAP EPS, supported by heavy institutional ownership and a confirmed market uptrend.

Datadog, Inc.

Datadog is positioned to lead the AI-data theme after revenue accelerated into the low- to mid-30% range while GAAP diluted EPS recovered and institutional ownership remains very high.

Harmony Biosciences Holdings, Inc.

Harmony Biosciences shows durable revenue and GAAP profit gains, with Q2 2026 revenue +30% YoY and GAAP diluted EPS +88% YoY, making it a timely specialty-biotech leader.

Waters Corp

Waters is a life‑science instruments leader showing a sharp revenue inflection with back-to-back quarters of >90% year-over-year growth and a verified Stage 1→2 breakout.

GEN Digital Inc.

RTX Corp

Snowflake Inc.

ELI LILLY & Co

Nvidia Corp

Datacenter revenue is still accelerating while the stock consolidates below highs.